Medications Are Not Enough: Interdisciplinary Treatment of Familial Chylomicronemia Syndrome in Pregnancy
A 28-year-old G2P1001 woman presents with epigastric pain and pancreatitis at 7 weeks and 4 days gestation. Her blood work results as “lipemic” specimens with an abnormal lipid panel, most notably with severely elevated triglycerides of 5,160 mg/dL. Abdominal ultrasound showed hepatosplenomegaly but did not visualize her pancreas well; CT/MRI were deferred because of her pregnancy.She had greater than fifty lifetime admissions for recurrent pancreatitis, the first at age 4. Her family is Southeast Asian, and her father and brother have recurrent pancreatitis too. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Rebecca Klahr, Samuel M Kim, Amrita Krishnamurthy Tags: Lipid Management through Nutrition, Supplements and Lifestyle Therapies Source Type: research
† Efficacy and Safety of Evinacumab in Pediatric Patients with Homozygous Familial Hypercholesterolemia
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder predominantly caused by mutations in the low-density lipoprotein (LDL) receptor gene and characterized by severely elevated LDL cholesterol (LDL-C) levels, beginning in utero. Although cardiovascular events often occur during childhood and adolescence in HoFH, few treatments effectively lower LDL-C in pediatric patients with HoFH. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Albert Wiegman, Susanne Greber-Platzer, Shazia Ali, Divya Singh, Yi Zhang, M Doortje Reijman, Eliot A Brinton, Min-Ji Charng, Shubba Srinivasan, Carissa Baker-Smith, Seth Baum, Julie Brothers, Jacob Hartz, Patrick M Moriarty, Poulabi Banerjee, Richard T G Tags: Lipid Management through Pharmacology Source Type: research
Evinacumab Reduces US Apheresis Eligibility in Patients with Homozygous Familial Hypercholesterolemia
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder that is often associated with extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) due to its impaired clearance from the circulation. Individuals with HoFH also experience increased cardiovascular events and premature mortality. Evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, has demonstrated approximately 50% reductions in LDL-C levels in patients with HoFH independent of residual LDL receptor function compared to placebo. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Fredrick J Raal, Jennifer McGinniss, Robert Pordy, Richard T Georga, Poulabi Banerjee, Jian Zhai, Shazia Ali, Patrick M Moriarty, Robert S Rosenson Tags: Lipid Management through Pharmacology Source Type: research
Timing of PCSK9i Initiation and Its Relationship with Clinical Outcomes in US Patients with Prior Cardiovascular Events: A Claims Database Analysis
Early and aggressive reduction of low-density lipoprotein cholesterol (LDL-C) has been linked to improved cardiovascular outcomes. Despite proven efficacy of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapies in lowering LDL-C and reducing risk of cardiovascular events, access to PCSK9i medications in the United States (US) has been limited for many eligible patients, leading to either delayed or no utilization. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Laura Martinez, Jasjit Kaur Multani, Kainan Sun, Bethany A Kalich, Margot Lisa Miglins, Eduard Sidelnikov, Usman Baber Tags: Lipid Management through Pharmacology Source Type: research
Rationale and Design of the Balance Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen in Patients with Familial Chylomicronemia Syndrome
Familial chylomicronemia syndrome (FCS) is a rare genetic cause of severe hypertriglyceridemia associated with an increased risk of acute pancreatitis (AP). Currently, no therapies are approved for FCS in the United States. Olezarsen, a ligand-conjugated antisense oligonucleotide (ASO), inhibits hepatic production of apolipoprotein (apo) C-III, a key regulator of LPL-mediated triglyceride (TG) lipolysis and non-LPL-mediated TG-rich lipoprotein hepatic uptake. In a phase 2 study of non-FCS patients with fasting serum TG levels of 200 –500 mg/dL, olezarsen demonstrated reduction in fasting TG levels of up to 60% vs placebo...
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Ewa Karwatowska-Prokopczuk, Veronica Alexander, Erik SG Stroes, Christie M Ballantyne, Henry N Ginsberg, Shuting Xia, Joseph L Witzum, Sotirios Tsimikas Tags: Lipid Management through Pharmacology Source Type: research
Using Virtual Reality and Other Immersive Tools to increase HCPs Ability to Differentially Diagnose and Manage FH
MLG launched the IMPACT initiative in 2021, which includes a variety of educational activities, including VR Rooms held at several associations ’ annual meetings in 2021 and 2022 and simulation-based online programming, that aims to increase learners’ ability to diagnose and treat FH. Learners have access to the IMPACT website (www.IMPACT-CVD.com) with HCP- and patient-facing tools to promote continuous education. Outcomes demonstrate h ow these advanced modalities result in greater knowledge and competency gains, practice improvements, and patient engagement in cardiology, pediatric cardiology and lipidology. (Source:...
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Lauren Welch Tags: Lipid Management through Pharmacology Source Type: research
Lipid Goals Achievement in Secondary Cardiovascular Prevention: Predictors of Success in a Large Multicentre Cohort Study in Greece
Guidelines require strict lipid goals (LGs) to obtain the maximal clinical benefits of lipid lowering therapies (LLT). Despite the widespread availability of effective LLT, evidence-based LGs for patients requiring cardiovascular preventive therapy, are infrequently achieved in everyday practice. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Rodis D. Paparodis, Ioannis Androulakis, Dimitrios Askitis, Ilias Perogamvros, Nicolaos Angelopoulos, Andreas Rizoulis, Sarantis Livadas, Anastasios Boniakos Tags: Lipid Management through Pharmacology Source Type: research
Lipid Goals Achievement in Secondary Cardiovascular Prevention: Predictors of Success in a Large Multicentre Cohort Study in Greece
Guidelines require strict Lipid Goals (LGs) to obtain the maximal clinical benefits of Lipid Lowering Therapies (LLT). Despite the widespread availability of effective LLT, evidence-based LGs for patients requiring cardiovascular preventive therapy, are infrequently achieved in everyday practice. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Rodis D. Paparodis, Ioannis Androulakis, Dimitrios Askitis, Ilias Perogamvros, Nicolaos Angelopoulos, Andreas Rizoulis, Sarantis Livadas, Anastasios Boniakos Tags: Lipid Management through Pharmacology Source Type: research
† Pegozafermin for the Treatment of Severe Hypertriglyceridemia, a Randomized, Double-blind, Placebo-controlled Phase 2 Trial (ENTRIGUE STUDY)
FGF21, an endogenous stress hormone, regulates glucose and lipid metabolism and energy expenditure. Pegozafermin (PGZ) is a long-acting glycopegylated recombinant analog of human fibroblast growth factor 21 (FGF21) being developed for severe hypertriglyceridemia (SHTG) and non-alcoholic steatohepatitis (NASH). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Deepak L Bhatt, Cynthia L Hartsfield, Harold E Bays, Michael Miller, Teresa Parli, Shibao Feng, Lulu Sterling, Germaine D Agollah, Hank Mansbach, John JP Kastelein, Toni Bransford Tags: Lipid Management through Pharmacology Source Type: research
Lipid lowering Effect of Dapagliflozin Alone versus Dapagliflozin- Saxagliptin Combination in Type 2 Diabetes (T2DM) Subjects
Effect of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) were examined on lipid parameters and inflammatory markers, pre and post therapy. Both Dapa (a SGLT2 receptor inhibitor) and Saxagliptin (a DPP4 enzyme inhibitor) are type 2 diabetes (T2DM) meds, but the combination has not been evaluated for cardiometabolic risk stratification. We hypothesized that Dapa will improve the outcomes when compared to placebo. We also postulated that the Combination of Dapagliflozin+Saxagliptin maybe even more efficient in lipid lowering compared to Dapagliflozin alone. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Sabyasachi Sen, Seshagiri Rao Nandula, Arad Jain Tags: Lipid Management through Pharmacology Source Type: research
Association between Niacin ER Use, Safety, and Cardiovascular Events: A Single Center Experience
Elevated lipoprotein(a) [Lp(a)] is associated with an increased incidence of heart attacks and strokes. Currently, an established relationship between Niacin ER and reduction in cardiovascular events is largely unknown. A single center study evaluated 85 patients with a prior history of cardiovascular events (27 with family history of premature cardiovascular events) whose Lipoprotein(a) levels were greater than 75nmol/L and were prescribed Niacin ER. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Halima Mushtaq Tabani, Chris M. Caraang Tags: Lipid Management through Pharmacology Source Type: research
Lifestyle Intervention in Primary Care Patients with Metabolic Syndrome
Increased consumption of calorie dense foods and decreased physical activity have led to high rates of obesity and its related diseases in the United States. Metabolic syndrome (MetS) is a group of clinical and metabolic abnormalities resulting from central obesity that is associated with increased rates of cardiovascular disease, type 2 diabetes, and mortality. Early identification and intervention in metabolic syndrome with lifestyle modification education has been shown to decrease rates of obesity, improve metabolic function, and reduce mortality. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Sommer Shackelford Tags: Metabolic Syndrome Source Type: research
Association of Physical Activity and Dietary Quality with Weight, Ectopic Fat, and Insulin Resistance in South Asian Men and Women: The MASALA Study
The South Asian population has a disproportionately higher risk for atherosclerotic cardiovascular disease (ASCVD) and ASCVD mortality compared to other ethnic groups. Unhealthy dietary patterns, lower physical activity, higher levels of insulin resistance and glucose intolerance, lower adiponectin levels, and higher lipoproteins have been implicated. The effects of activity levels and dietary quality on weight, body fat, and insulin resistance among South Asians is not well understood. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Cynthia Azam Ponir, Parag Anilkumar Chevli, Alka Kanaya, Meghana Gadgil, Luis A Rodriguez, Bharathi Upadhya, Morgana Mongraw-Chaffin Tags: Metabolic Syndrome Source Type: research
Nuclear Magnetic Resonance Analysis of Serum Amino Acids, General Health Parameters, and Keto-Acids
Serum metabolomic parameters, especially amino acids, play an important role in neurologic and muscle function, physical performance, and overall cardiovascular and general health. Moreover, serum keto-acids are useful for assessing carbohydrate metabolism and managing seizures. Analysis of serum by nuclear magnetic resonance (NMR) can simultaneously assess metabolomic and lipid and lipoprotein parameters. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Sarah E Flowers, Ernst J Schaefer, Marianna Fernandes, Margaret R Diffenderfer, Lihong He Tags: Metabolic Syndrome Source Type: research
The Prediction and Prevention of Diabetes Mellitus
Diabetes mellitus is a major cause of morbidity and mortality. Diabetes is also a major cause of kidney failure, neuropathy, and blindness. Lifestyle change decreases diabetes risk. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Ernst J Schaefer, Masumi Ali, Joi A Gleason, Ching-ti Liu, Michael L Dansinger Tags: Metabolic Syndrome Source Type: research
